Prostera Dosage/Direction for Use

Adults: For the treatment of hypertension: The dose of terazosin should be managed according to each patient's response. For the different dosage regimens, suitable strengths are available.
The starting dose for all patients is 1 mg before bedtime and this should not be exceeded during the first week of treatment. Patients should be advised to comply in order to avoid first-dose hypotensive effect. The dose can be increased by approximately doubling the dose at weekly intervals until effective control of blood pressure is established.
The usual maintenance dose is 2 mg daily. However, for certain patients, an increased dose may become necessary. A maximum dose of 20 mg should not be exceeded. Reduction of dose should be undertaken when adding other antihypertensive medication followed by re-titration if required.
For the symptomatic treatment of urinary obstruction caused by BPH: The dose of terazosin should be managed according to each patient's response.
Patients should be advised to comply in order to avoid first-dose hypotensive effect.
The starting dose for all patients is 1 mg at night-time for 7 days and this should not be exceeded during the first week of treatment. The dose can then be increased to 2 mg daily for 14 days, followed by 5 mg daily for 7 days. Response to treatment must be reviewed at four weeks. Transient side effects may occur at each titration step. If any side effects persist, consideration should be given to reducing the dose.
The usual recommended dose is 5 mg once daily. The maximum daily dose is 10 mg.
Terazosin therapy of hypertension is a long-term treatment, which should only be interrupted on medical advice. If it is necessary to stop terazosin therapy, the dose should be re-titrated starting with 1 mg terazosin at bedtime.
Use in patients with impaired renal function or the elderly: In general, terazosin should not be used in patients with a reduced urinary outflow or anuria or an advanced renal deficiency.
No dosage adjustments are required in the elderly.
Use in patients with hepatic impairment: The terazosin dose should be titrated with particular caution in patients with impaired liver function since terazosin undergoes extensive hepatic metabolism and is mainly excreted by the biliary tract. As no clinical experience is available in patients with severe hepatic dysfunction, the use of terazosin is not recommended in these patients.
Use in children and adolescents: There are no reports regarding the efficacy and safety of the medicinal product in children and adolescents under the age of 18 years. Therefore, the use of terazosin is not recommended for this group.
Method of administration: Terazosin tablets should be swallowed whole and not chewed and can be taken with or without food.